Catch-up Immunization Schedule
Ages 7 - 18 Years

• 2012 Schedules PDF (adobe acrobat)

• 2012 Schedule for ages 0-6 years | catch-up schedule

• 2012 Schedule for ages 7-18 years | catch-up schedule

• 2012 Schedule for Adults | special

• The maximum age for the first dose in the series is 14 weeks, 6 days; and 8 months, 0 days for the final dose in the series. Vaccination should not be initiated for infants aged 15 weeks, 0 days or older.
• If Rotarix was administered for the first and second doses, a third dose is not indicated.

• The fifth dose is not necessary if the fourth dose was administered at age 4 years or older.

• Hib vaccine should be considered for unvaccinated persons aged 5 years or older who have sickle cell disease, leukemia, human immunodeficiency virus (HIV) infection, or anatomic/functional asplenia.
• If the first 2 doses were PRP-OMP (PedvaxHIB or Comvax) and were administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose.
• If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a final dose at age 12 through 15 months.

• For children aged 24 through 71 months with underlying medical conditions, administer 1 dose of PCV if 3 doses of PCV were received previously, or administer 2 doses of PCV at least 8 weeks apart if fewer than 3 doses of PCV were received previously
• A single dose of PCV may be administered to certain children aged 6 through 18 years with underlying medical conditions. See age-specific schedules for details.
• Administer pneumococcal polysaccharide vaccine (PPSV) to children aged 2 years or older with certain underlying medical conditions.  See MMWR 2010;59(No. RR-11).

• A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months following the previous dose.
• In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk for imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
• IPV is not routinely recommended for U.S. residents aged 18 years or older.

• See Figure 1 (“Recommended immunization schedule for persons aged 0 through 6 years”) and Figure 2 (“Recommended immunization schedule for persons aged 7 through 18 years”) for further guidance.

• Administer the second dose routinely at age 4 through 6 years.

• Administer the second dose routinely at age 4 through 6 years.
• If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.

• For children aged 7 through 10 years who are not fully immunized with the childhood DTaP vaccine series, Tdap vaccine should be substituted for a single dose of Td vaccine in the catch-up series; if additional doses are needed, use Td vaccine. For these children, an adolescent Tdap vaccine dose should not be given.
• An inadvertent dose of DTaP vaccine administered to children aged 7 through 10 years can count as part of the catch-up series. This dose can count as the adolescent Tdap dose, or the child can later receive a Tdap booster dose at age 11–12 years.

• Administer the vaccine series to females (either HPV2 or HPV4) and males (HPV4) at age 13 through 18 years if patient is not previously vaccinated.
• Use recommended routine dosing intervals for vaccine series cacth-up; see Figure 2 (“Recommended immunization schedule for persons aged 7 through 18 years”).

This page was last updated on February 08, 2012